<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pure red cell aplasia (PRCA) due to anti-erythropoiesis-stimulating agent antibodies
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pure red cell aplasia (PRCA) due to anti-erythropoiesis-stimulating agent antibodies
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pure red cell aplasia (PRCA) due to anti-erythropoiesis-stimulating agent antibodies
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey S Berns, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steve J Schwab, MD, FACP, FASN
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric N Taylor, MD, MSc, FASN
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 27, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acquired pure red cell aplasia (PRCA) is a rare condition of profound anemia characterized by a very low reticulocyte count and the virtual absence of erythroid precursors in the bone marrow. All other cell lines are present and seem quantitatively and morphologically normal. Many cases of acquired PRCA are idiopathic. In others, underlying conditions, such as thymoma, myelodysplastic syndromes, lymphoma, leukemia, systemic autoimmune disorders, and viral infection (ie, parvovirus B19), or treatment with drugs, such as
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         or
         <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">
          chloramphenicol
         </a>
         , are identified [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7120.html" rel="external">
          "Acquired pure red cell aplasia in adults"
         </a>
         .)
        </p>
        <p>
         PRCA has also been described in patients treated with epoetin and other erythropoiesis-stimulating agents (ESAs), resulting from the induction of neutralizing antibodies directed against the erythropoietin (EPO) molecule [
         <a href="#rid2">
          2
         </a>
         ]. Most reported cases have been in patients receiving epoetin for chronic kidney disease (CKD)-related anemia.
        </p>
        <p>
         PRCA due to anti-EPO antibodies in patients with CKD will be reviewed here. A discussion of other causes of acquired PRCA is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/7120.html" rel="external">
          "Acquired pure red cell aplasia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ETIOLOGY AND PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most cases of non-erythropoietin (EPO)-related PRCA are mediated by immunoglobulin G (IgG) autoantibodies or cytotoxic T lymphocytes directed against erythroid precursor or progenitor cells [
         <a href="#rid1">
          1,3
         </a>
         ]. Inhibition of erythropoiesis occurs primarily between the colony forming unit–erythroid (CFU-E) and proerythroblast stages. The proerythroblast is the first morphologically identifiable erythroid precursor in normal marrow and is virtually absent in the marrow of patients with PRCA. (See
         <a class="medical medical_review" href="/z/d/html/7120.html" rel="external">
          "Acquired pure red cell aplasia in adults"
         </a>
         .)
        </p>
        <p>
         PRCA due to autoantibodies against endogenous EPO is rare in patients who have never been treated with erythropoiesis-stimulating agents (ESAs) [
         <a href="#rid4">
          4-6
         </a>
         ]. The serum of patients with EPO-related PRCA inhibits the growth of erythroid progenitor cells in bone marrow cultures [
         <a href="#rid2">
          2
         </a>
         ]. Neutralizing IgG antibodies to the protein component of exogenous ESAs crossreact with endogenous EPO.
        </p>
        <p>
         There are several preparations of epoetins (ie,
         <a class="drug drug_general" data-topicid="9410" href="/z/d/drug information/9410.html" rel="external">
          epoetin alfa
         </a>
         , epoetin beta, epoetin omega, and others) produced by various manufacturers around the world. They differ from one another and from the native hormone in terms of glycosylation and sialic acid content [
         <a href="#rid7">
          7
         </a>
         ]. The vast majority of cases of EPO-related PRCA have occurred in patients treated with a particular epoetin alfa product (Eprex, in single-use syringes), which was manufactured and distributed outside the United States. Altered antigenicity of this specific product has been suggested as the underlying cause of anti-EPO antibody development. However, EPO-related PRCA has been described with other preparations including
         <a class="drug drug_general" data-topicid="8662" href="/z/d/drug information/8662.html" rel="external">
          darbepoetin alfa
         </a>
         and
         <a class="drug drug_general" data-topicid="101636" href="/z/d/drug information/101636.html" rel="external">
          methoxy polyethylene glycol-epoetin beta
         </a>
         [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
         Virtually all reported cases of anti-EPO antibody-mediated PRCA have occurred in patients with chronic kidney disease (CKD) who have received the drug subcutaneously [
         <a href="#rid2">
          2,10-12
         </a>
         ]. Although not specifically studied with epoetin, subcutaneous administration of other drugs has been associated with greater immunogenicity than with intravenous (IV) administration [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most cases of erythropoietin (EPO)-related PRCA occurred in patients with kidney failure in Europe and the United Kingdom, but patients in Canada, Australia, and countries in Asia have also been affected [
         <a href="#rid10">
          10,14
         </a>
         ].
        </p>
        <p>
         The condition remains extremely rare, given the widespread use of epoetin and other erythropoiesis-stimulating agents (ESAs) [
         <a href="#rid15">
          15-17
         </a>
         ]. The overall incidence of reported cases between 1989 and June 2004 was 1.6 per 10,000 patient-years of subcutaneous exposure [
         <a href="#rid18">
          18
         </a>
         ]. There have been only a few cases reported in patients treated with intravenously (IV) administered epoetin, with an incidence of 0.02 per 10,000 patient-years of exposure [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Eprex
         </span>
         <span class="headingEndMark">
          —
         </span>
         There have been over 200 reported cases of PRCA related to Eprex use [
         <a href="#rid20">
          20
         </a>
         ], representing the vast majority of affected patients [
         <a href="#rid10">
          10,14
         </a>
         ]. There was a substantial increase in the number of reported cases between 2001 and 2003, almost exclusively in patients with chronic kidney disease (CKD) who received Eprex subcutaneously [
         <a href="#rid10">
          10,14,18
         </a>
         ].
        </p>
        <p>
         This increase in the number of cases was later discovered to coincide with the release of a new formulation and packaging of this epoetin, as discussed above. The incidence was 3.43 per 10,000 patient-years of exposure for Eprex supplied in syringes with uncoated rubber stoppers compared with 0.23 and 0.17 per 10,000 patient-years for Eprex preparations in coated rubber-stopper syringes and stabilized with human serum albumin (HSA), respectively.
        </p>
        <p>
         One report of the multinational Prospective Immunogenicity Surveillance Registry (PRIMS) described five confirmed episodes of EPO-related PRCA [
         <a href="#rid21">
          21
         </a>
         ]. Three episodes occurred with a reformulated Eprex preparation, and two occurred with other ESAs among over 15,000 patients, with an incidence (per 100,000 patient-years) of 35.8 for Eprex and 14 for other ESAs (rate ratio 2.56, 95% CI 0.43-15.31), which was not statistically significantly different.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Non-Eprex cases
         </span>
         <span class="headingEndMark">
          —
         </span>
         The overall incidence of reported cases between 1989 and 2004 of PRCA with subcutaneous use of non-Eprex preparations was much lower, ranging from 0.02 to 0.16 per 10,000 patient-years between 1989 and 2004, depending on the preparation [
         <a href="#rid10">
          10,14,17,22-26
         </a>
         ]. Fortunately, EPO PRCA has become exceedingly rare since 2005, with only isolated case reports of PRCA associated with epoetin,
         <a class="drug drug_general" data-topicid="8662" href="/z/d/drug information/8662.html" rel="external">
          darbepoetin
         </a>
         , and
         <a class="drug drug_general" data-topicid="101636" href="/z/d/drug information/101636.html" rel="external">
          methoxy polyethylene glycol-epoetin beta
         </a>
         [
         <a href="#rid26">
          26,27
         </a>
         ].
        </p>
        <p>
         EPO antibody-mediated PRCA has only rarely been reported in children with kidney failure [
         <a href="#rid14">
          14,28
         </a>
         ].
        </p>
        <p>
         "Biosimilar" epoetin products are becoming increasingly available around the world; treatment with these agents has also been associated with development of anti-EPO both non-neutralizing and neutralizing antibodies, with a notable outbreak in Thailand related to subcutaneous use of a biosimilar produced outside the United States and the European Union [
         <a href="#rid29">
          29-32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          SCREENING FOR ANTI-EPO ANTIBODIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among dialysis patients, routine screening for the presence of anti-erythropoietin (EPO) antibodies cannot be justified. This was shown in a study involving five centers in Canada, in which approximately 1500 hemodialysis, peritoneal dialysis, and predialysis patients were screened [
         <a href="#rid33">
          33
         </a>
         ]. Using a radioimmunoprecipitation assay (RIPA), a low-positive test was noted in only one patient (who had previously been diagnosed with PRCA), and borderline positive assays were observed in only three individuals, none of whom had signs of PRCA. None of the four had neutralizing anti-EPO antibodies.
        </p>
        <p>
         Similar results were obtained in 536 patients screened in 35 German dialysis units [
         <a href="#rid34">
          34
         </a>
         ]. In this study, anti-EPO antibodies were detected in three EPO-hyporesponsive and three EPO-normoresponsive patients using an enzyme-linked immunosorbent assay (ELISA), with only one borderline result with a RIPA. There were no cases of PRCA.
        </p>
        <p>
         However, we agree with the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, which suggest that an evaluation for PRCA due to anti-EPO antibodies should occur in the patient exposed to at least eight weeks of erythropoiesis-stimulating agent (ESA) therapy who develops all of the following [
         <a href="#rid35">
          35
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decline in hemoglobin (Hb) level of &gt;0.5 to 1 g/dL per week or transfusion requirement of at least one to two units per week to maintain adequate Hb
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Normal platelet and white blood cell (WBC) count
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absolute reticulocyte count of &lt;10,000/microL
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         PRCA due to anti-erythropoietin (EPO) antibodies should be suspected if the hemoglobin (Hb) level declines by &gt;2 g/dL per month or the reticulocyte count is &lt;20,000/microL in an individual who has previously responded to EPO. PRCA generally does not occur, unless the patient has been on EPO for at least three to four weeks, and typically occurs after 6 to 18 months of exposure [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         PRCA is specifically characterized by the following clinical features [
         <a href="#rid10">
          10,36
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decline in Hb level of &gt;0.7 to 1 g/dL per week without transfusions or transfusion requirement of at least one unit per week to maintain adequate Hb, despite continued use of EPO at the same or increased doses
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Markedly reduced reticulocyte count (&lt;10,000/microL)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drop in platelet counts, although generally not below the lower limit of normal
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Normal white blood cell (WBC) count
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated serum transferrin saturation and serum ferritin, reflecting decreased utilization of iron secondary to diminished erythropoiesis
        </p>
        <p>
        </p>
        <p>
         Allergic urticarial skin reactions at sites of earlier subcutaneous EPO injections have also been described [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          EVALUATION AND DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         To properly diagnose the disorder, a bone marrow aspirate and evaluation for the presence of anti-erythropoietin (EPO) antibodies must be performed.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Bone marrow aspirate
         </span>
         <span class="headingEndMark">
          —
         </span>
         The bone marrow aspirate reveals severe erythroid hypoplasia, with &lt;5 percent red blood cell precursors; evidence of a block in the maturation of erythroid precursors may be present. Platelet and white cell precursors are entirely normal.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Anti-EPO antibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Identification of antibodies to EPO is a critical component of the diagnosis. There are several available tests to detect antibodies that bind EPO, each with its own advantages and disadvantages [
         <a href="#rid38">
          38
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Radioimmunoprecipitation assay (RIPA) appears to be the most accurate test for detecting anti-EPO antibodies. However, it is not standardized, may not detect low-affinity antibodies, requires radiolabeled antigen, and is time consuming and difficult to automate [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Enzyme-linked immunosorbent assays (ELISAs) are more widely available but appear to have lower sensitivity and specificity than the RIPA [
         <a href="#rid10">
          10,39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A biosensor assay, which is not as readily available as the previous two assays, may provide better characterization of detected antibodies (ie, binding affinity and isotype). However, it may detect very low-affinity antibodies in baseline sera that never cause PRCA.
        </p>
        <p>
        </p>
        <p>
         In general, these assays can detect antibodies with a concentration of at least 500 ng/mL [
         <a href="#rid38">
          38
         </a>
         ]. The neutralizing capability of the anti-EPO antibodies cannot be assessed with any of the above-mentioned assays. This requires a bioassay in which patient serum or immunoglobulin inhibits red blood cell precursor growth in bone marrow or cell line cultures [
         <a href="#rid10">
          10,36
         </a>
         ]. In addition, non-neutralizing antibodies may be more common than neutralizing antibodies [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         It is difficult to recommend use of any one of these assays over another given that they are not standardized, have advantages and disadvantages that are difficult to compare, and are not available commercially [
         <a href="#rid40">
          40
         </a>
         ]. The World Health Organization (WHO) established an EPO-antibody reference panel that should be useful for assay standardization and improving diagnostic accuracy [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         The sample in a suspected case may be sent to the manufacturer, where several different assays, including one for neutralizing capability, are performed [
         <a href="#rid42">
          42
         </a>
         ]. Confirmation of a suspected case of anti-EPO antibody-mediated PRCA should show the presence of anti-EPO antibodies and evidence of neutralizing ability [
         <a href="#rid14">
          14,36
         </a>
         ]. Bioassays generally detect antibodies with a concentration of at least 1 mcg/mL [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to PRCA due to anti-erythropoietin (EPO) antibodies, there are a large number of other causes of anemia and hyporesponsiveness to EPO among patients with chronic kidney disease (CKD). They can be distinguished from PRCA largely because of the observation that PRCA due to anti-EPO antibodies is associated with a profound fall in hemoglobin (Hb) level and reticulocyte count [
         <a href="#rid38">
          38
         </a>
         ]. By comparison, the other causes of EPO resistance are associated with less severe drops in counts. Other causes of EPO resistance are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1935.html" rel="external">
          "Hyporesponse to erythropoiesis-stimulating agents (ESAs) in chronic kidney disease", section on 'Causes'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is limited experience with managing PRCA. Treatment consists of:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initial management including transfusions for symptomatic anemia and discontinuing all recombinant erythropoietin (EPO) products
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunosuppressive therapy to eradicate antibodies
        </p>
        <p>
        </p>
        <p>
         Among patients who do not respond to immunosuppressive therapies and are eligible candidates, consideration should be given to kidney transplantation.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Initial management
         </span>
         <span class="headingEndMark">
          —
         </span>
         The two most important initial steps in management in anti-EPO antibody-mediated PRCA are transfusions for symptomatic anemia and stopping all recombinant EPO products [
         <a href="#rid10">
          10
         </a>
         ]. There are at least three observations underlying the recommendation to avoid
         <strong>
          any
         </strong>
         recombinant EPO preparation, including
         <a class="drug drug_general" data-topicid="8662" href="/z/d/drug information/8662.html" rel="external">
          darbepoetin alfa
         </a>
         , in patients with anti-EPO antibody-mediated PRCA:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anti-EPO antibodies crossreact not only with the endogenous hormone, but also with all recombinant EPO molecules, including
         <a class="drug drug_general" data-topicid="8662" href="/z/d/drug information/8662.html" rel="external">
          darbepoetin alfa
         </a>
         [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rechallenge with EPO preparations may cause an anamnestic antibody response, making it less possible for the antibody to either spontaneously disappear or return to clinically unimportant levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rechallenge with EPO may incite the formation of allergic skin and systemic reactions (eg, anaphylaxis), which might further complicate the patient's clinical picture [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         However, there have been case reports of patients who have tolerated rechallenge [
         <a href="#rid8">
          8,43-48
         </a>
         ]. Despite these case reports and other isolated instances in which patients appeared to tolerate resumption of EPO therapy or other EPO preparations, in some instances with concomitant immunosuppression [
         <a href="#rid43">
          43,49
         </a>
         ], patients with EPO-associated PRCA should have EPO treatment discontinued and should not routinely be switched to an alternative EPO product or to
         <a class="drug drug_general" data-topicid="8662" href="/z/d/drug information/8662.html" rel="external">
          darbepoetin alfa
         </a>
         .
        </p>
        <p>
         If, however, rechallenge is considered for clinical reasons or at the patient's request, the following practice appears reasonable [
         <a href="#rid46">
          46
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rechallenge only if anti-EPO antibody levels are below the lower limit of detection
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monitor the absolute reticulocyte count and anti-EPO antibody levels and for systemic reactions
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administer
         <a class="drug drug_general" data-topicid="101636" href="/z/d/drug information/101636.html" rel="external">
          methoxy polyethylene glycol-epoetin beta
         </a>
         , rather than EPO or
         <a class="drug drug_general" data-topicid="8662" href="/z/d/drug information/8662.html" rel="external">
          darbepoetin
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administer
         <a class="drug drug_general" data-topicid="101636" href="/z/d/drug information/101636.html" rel="external">
          methoxy polyethylene glycol-epoetin beta
         </a>
         intravenously, rather than subcutaneously, whenever feasible
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Immunosuppressive therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Since PRCA in this setting is immune mediated, the condition should respond to immunosuppressive therapy, and, while spontaneous remissions after cessation of EPO therapy occur, they appear to be rare; immunosuppressive therapy should probably be provided in most cases [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         There are no controlled data, but several different immunosuppressive regimens have been used. In one retrospective review of 47 cases in Europe [
         <a href="#rid50">
          50
         </a>
         ], EPO therapy was stopped in all patients. Ten patients did not receive immunosuppressive therapy, one died within six weeks of diagnosis, and nine did not recover by a median follow-up of 12 months.
        </p>
        <p>
         The remaining 37 patients were treated with a variety of immunosuppressive agents. The majority received steroids, alone or in combination with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG), or plasmapheresis; six received
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         alone; one received
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil; and two received
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         . Six patients received a kidney transplant. The following results were reported:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seventy-eight percent of all patients recovered, most within three months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recovery occurred only after antibody levels became undetectable.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No relapse of PRCA occurred following cessation of immunosuppression, but none of the patients were rechallenged with EPO or
         <a class="drug drug_general" data-topicid="8662" href="/z/d/drug information/8662.html" rel="external">
          darbepoetin alfa
         </a>
         following recovery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All six patients who received a kidney transplant recovered.
        </p>
        <p>
        </p>
        <p>
         Favorable responses were seen with many of the regimens. This included corticosteroids with or without
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         (10 of 18 recovered) and corticosteroids with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         (seven of eight recovered), as well as with
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         alone (four of six recovered), which resulted in the fastest response [
         <a href="#rid50">
          50,51
         </a>
         ]. In this study, none of the patients treated with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , an antibody against B cells that has been effective for non-EPO-related PRCA, recovered [
         <a href="#rid50">
          50
         </a>
         ], although response to rituximab has been reported elsewhere [
         <a href="#rid52">
          52,53
         </a>
         ]. Only one of nine patients who were treated with IVIG alone recovered.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          Tacrolimus
         </a>
         has also been used successfully in a case report [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         In one review, there was an analysis of EPO-related PRCA, as reported to the US Food and Drug Administration (FDA) and the manufacturers of several EPO preparations, as well as longer-term follow-up of patients previously reported and described above from the European PRCA Study Group [
         <a href="#rid50">
          50
         </a>
         ]. It was concluded that the highest recovery rates were associated with combination
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         and
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         and that the highest rates of EPO responsiveness on rechallenge were in those patients whose anti-EPO antibody levels were undetectable [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         The treatment recommendations that follow are made with the caveat that worldwide experience is very limited, and none of the data are from randomized, controlled trials. Given that the highest recovery rates appear to be associated with combination
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         and
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , we prefer initial therapy consisting of prednisone (1 mg/kg per day) plus oral cyclophosphamide (50 to 100 mg per day). A reasonable alternative is
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         alone at a dose of 200 mg per day (or 100 mg twice per day) [
         <a href="#rid46">
          46,55
         </a>
         ]. Patients who do not respond to treatment with either oral cyclophosphamide plus prednisone or with cyclosporine alone may be treated with the other regimen;
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         may also be considered as an alternative to cyclosporine. (See
         <a class="medical medical_review" href="/z/d/html/7963.html" rel="external">
          "General principles of the use of cyclophosphamide in rheumatic diseases"
         </a>
         .)
        </p>
        <p>
         The cost, potential toxicities, and limited effectiveness [
         <a href="#rid50">
          50
         </a>
         ] of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         suggest that these treatments should perhaps be limited to those who fail to respond to other therapy. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy"
         </a>
         .)
        </p>
        <p>
         The optimal duration of immunosuppressive therapy and monitoring for anti-EPO antibody-mediated PRCA is unknown. However, the following recommendations appear reasonable:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Continue treatment until antibody levels become undetectable; discontinue treatment three or four months after initiation among patients with no response.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monitor hemoglobin (Hb) weekly to assess for transfusion requirement and response to therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monitor reticulocyte count and anti-EPO antibody levels every one to two weeks during treatment to assess response or lack thereof.
        </p>
        <p>
        </p>
        <p>
         Since the majority of patients who respond to treatment do so within three to four months, immunosuppressive therapy should probably be discontinued if there is no response within this time. However, in the abovementioned study of 37 treated patients, 4 patients responded 5 to 18 months after treatment was initiated [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         With the introduction of "biosimilar" epoetins and increasing use of unlicensed epoetin products in certain parts of the world, ongoing vigilance must be maintained for new occurrences of anti-EPO antibody-mediated PRCA [
         <a href="#rid32">
          32,56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H735979649">
         <span class="h2">
          Hypoxia-inducible factor prolyl hydroxylase inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF PHIs) are a class of oral drugs that stimulate the production of endogenous erythropoietin and are an alternative option to ESAs for patients with EPO-associated PRCA. We do not use HIF PHIs to treat anemia in patients with CKD who are not on dialysis, because the safety of HIF PHIs in this population has not been established. Our approach to the use of HIF PHIs in patients on dialysis is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1926.html" rel="external">
          "Treatment of anemia in patients on dialysis", section on 'Choice of therapy in iron replete patients'
         </a>
         .)
        </p>
        <p>
         Data supporting the use of HIF-PHIs for the management of anemia in patients with EPO-associated PRCA are limited to case reports [
         <a href="#rid57">
          57-61
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etiology and pathogenesis
         </strong>
         – The vast majority of cases of recombinant human erythropoietin (EPO)-related acquired pure red cell aplasia (PRCA) have occurred in patients treated with a particular
         <a class="drug drug_general" data-topicid="9410" href="/z/d/drug information/9410.html" rel="external">
          epoetin alfa
         </a>
         product: Eprex (in single-use syringes). The underlying cause may be organic compounds (leached by polysorbate from uncoated rubber stoppers in prefilled syringes) that are acting as adjuvants, resulting in anti-EPO antibody development. Virtually all reported cases of anti-EPO antibody-mediated PRCA have occurred in patients with chronic kidney disease who have received the drug subcutaneously. (See
         <a class="local">
          'Etiology and pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – EPO-related PRCA remains extremely rare, given the widespread use of erythropoiesis-stimulating agent (ESAs). There have been &gt;200 reported cases of PRCA related to Eprex use, which represent the vast majority of affected patients. Following changes in storage and handling recommendations and discontinuation of subcutaneous administration of Eprex, the incidence of anti-EPO antibody-mediated PRCA in patients with kidney disease has declined. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – EPO-induced PRCA should be considered in the patient with significant anemia who has been treated with epoetin or another ESA for at least three to four weeks and has previously responded to treatment. The condition is characterized by a sudden decline in hemoglobin (Hb) level despite continued use of the ESA, markedly reduced reticulocyte count, and normal white blood cell (WBC) and platelet counts. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – To definitively diagnose EPO-induced PRCA, a bone marrow aspirate and evaluation for the presence of neutralizing anti-EPO antibodies should be performed. The bone marrow reveals severe erythroid hypoplasia, with &lt;5 percent red blood cell precursors, and there may be evidence of a block in the maturation of erythroid precursors. Platelet and white cell precursors are entirely normal. Anti-EPO antibodies are detected by radioimmunoprecipitation assay (RIPA), enzyme-linked immunosorbent assays (ELISAs), or other assay, as available. The sample must be sent to the manufacturer for testing to document the presence of anti-EPO antibodies and evidence of their neutralizing ability. (See
         <a class="local">
          'Evaluation and diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stop recombinant ESAs
         </strong>
         – We recommend the cessation of all recombinant ESAs in patients with PRCA (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). We also recommend
         <strong>
          not
         </strong>
         switching to an alternative ESA (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). Patients should be transfused for severe symptomatic anemia. (See
         <a class="local">
          'Immunosuppressive therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initiate immunosuppressive therapy
         </strong>
         – Given that spontaneous remissions after cessation of epoetin therapy are rare, we recommend the administration of immunosuppressive therapy in most patients (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). We suggest initial therapy consisting of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (1 mg/kg per day) plus oral
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         (50 to 100 mg per day) for a maximum of three to four months (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). A reasonable alternative for first-line therapy is
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         alone at a dose of 200 mg per day (or 100 mg twice per day) for a maximum of three to four months. Patients who do not respond to initial treatment with either oral cyclophosphamide plus prednisone or with cyclosporine alone may be subsequently treated with the other regimen.
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          Tacrolimus
         </a>
         may also be considered as an alternative to cyclosporine. (See
         <a class="local">
          'Immunosuppressive therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7963.html" rel="external">
          "General principles of the use of cyclophosphamide in rheumatic diseases"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitor response to therapy
         </strong>
         – The optimal duration of immunosuppressive therapy and monitoring for anti-EPO antibody-mediated PRCA is unknown. However, the following recommendations appear reasonable (see
         <a class="local">
          'Immunosuppressive therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7963.html" rel="external">
          "General principles of the use of cyclophosphamide in rheumatic diseases"
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Continue treatment until antibody levels become undetectable; discontinue treatment three or four months after initiation among patients with no response.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Monitor Hb weekly to assess for transfusion requirement and response to therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Monitor absolute reticulocyte count and anti-EPO antibody levels every one to two weeks during treatment to assess response or lack thereof.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subsequent treatment of anemia
         </strong>
         – Rechallenge may be considered in patients in whom anti-EPO antibody levels are below or closer to the lower limit of detection. If performed, we recommend administration of the
         <a class="drug drug_general" data-topicid="101636" href="/z/d/drug information/101636.html" rel="external">
          methoxy polyethylene glycol-epoetin beta
         </a>
         intravenously in hemodialysis patients. The Hb, reticulocyte count, and anti-EPO antibody levels should be closely monitored. Hypoxia-inducible factor prolyl hydroxylase inhibitors are an alternative option to ESAs for selected patients with EPO-associated PRCA. (See
         <a class="local">
          'Initial management'
         </a>
         above and
         <a class="local">
          'Hypoxia-inducible factor prolyl hydroxylase inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4145978958">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Stanley L Schrier, MD (deceased), who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Fisch P, Handgretinger R, Schaefer HE. Pure red cell aplasia. Br J Haematol 2000; 111:1010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krantz S. Anemia due to bone marrow failure: diagnosis and treatment. Compr Ther 1980; 6:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peschle C, Marmont AM, Marone G, et al. Pure red cell aplasia: studies on an IgG serum inhibitor neutralizing erythropoietin. Br J Haematol 1975; 30:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bunn HF. Drug-induced autoimmune red-cell aplasia. N Engl J Med 2002; 346:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casadevall N, Dupuy E, Molho-Sabatier P, et al. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 1996; 334:630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Storring PL, Tiplady RJ, Gaines Das RE, et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998; 100:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shingu Y, Nakata T, Sawai S, et al. Antibody-mediated pure red cell aplasia related with epoetin-beta pegol (C.E.R.A.) as an erythropoietic agent: case report of a dialysis patient. BMC Nephrol 2020; 21:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Padhi S, Behera G, Pattnaik SA, et al. Acquired Pure Red Cell Aplasia Following Recombinant Erythropoietin (Darbepoetin-alfa) Therapy. Indian J Nephrol 2020; 30:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossert J, Casadevall N, Eckardt KU. Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol 2004; 15:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eckardt KU, Casadevall N. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant 2003; 18:865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quint L, Casadevall N, Giraudier S. Pure red cell aplasia in patients with refractory anaemia treated with two different recombinant erythropoietins. Br J Haematol 2004; 124:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002; 24:1720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004; 351:1403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prabhakar SS, Muhlfelder T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol 1997; 47:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peces R, de la Torre M, Alcázar R, Urra JM. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 1996; 335:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gershon SK, Luksenburg H, Coté TR, Braun MM. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2002; 346:1584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005; 67:2346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cournoyer D, Toffelmire EB, Wells GA, et al. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol 2004; 15:2728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macdougall IC. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks. Nephrol Dial Transplant 2005; 20 Suppl 4:iv9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macdougall IC, Casadevall N, Locatelli F, et al. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). Nephrol Dial Transplant 2015; 30:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macdougall IC. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another. Curr Med Res Opin 2004; 20:83.
          </a>
         </li>
         <li class="breakAll">
          Amgen Statement on Pure Red Cell Aplasia www.amgen.com/clinicians/prca.html (Accessed on March 07, 2005).
         </li>
         <li class="breakAll">
          Janssen Research and Development Case Reports www.jnjpharmarnd.com/company/n-casereports.html. (Accessed on December 13, 2005).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Locatelli F, Del Vecchio L, Pozzoni P. Pure red-cell aplasia "epidemic"--mystery completely revealed? Perit Dial Int 2007; 27 Suppl 2:S303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKoy JM, Stonecash RE, Cournoyer D, et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008; 48:1754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okahashi N, Kubo M, Hoshino E, et al. Successful Treatment of Antibody-mediated Pure Red Cell Aplasia Induced by Continuous Erythropoietin Receptor Activator with Prednisolone. Intern Med 2022; 61:2209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alonso Melgar A, Melgosa Hijosa M, Pardo de la Vega R, et al. Antierythropoietin antibody-induced pure red cell aplasia: posttransplant evolution. Pediatr Nephrol 2004; 19:1059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 2011; 80:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haag-Weber M, Eckardt KU, Hörl WH, et al. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol 2012; 77:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panichi V, Ricchiuti G, Scatena A, et al. Pure red cell aplasia induced by epoetin zeta. Clin Kidney J 2016; 9:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishbane S, Singh B, Kumbhat S, et al. Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease. Clin J Am Soc Nephrol 2018; 13:1204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu G, Wadgymar A, Wong G, et al. A cross-sectional immunosurveillance study of anti-EPO antibody levels in CRF patients receiving epoetin alfa in 5 Ontario Renal Centers. Am J Kidney Dis 2004; 44:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stoffel MP, Haverkamp H, Kromminga A, et al. Prevalence of anti-erythropoietin antibodies in hemodialysis patients without clinical signs of pure red cell aplasia. Comparison between hypo- and normoresponsive patients treated with epoetins for renal anemia. Nephron Clin Pract 2007; 105:c90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapter 1: Diagnosis and evaluation of anemia in CKD. Kidney Int Suppl (2011) 2012; 2:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casadevall N, Cournoyer D, Marsh J, et al. Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. Eur J Haematol 2004; 73:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber G, Gross J, Kromminga A, et al. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol 2002; 13:2381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pollock C, Johnson DW, Hörl WH, et al. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol 2008; 3:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swanson SJ, Ferbas J, Mayeux P, Casadevall N. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin Pract 2004; 96:c88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thorpe R, Swanson SJ. Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures. Nephrol Dial Transplant 2005; 20 Suppl 4:iv16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wadhwa M, Mytych DT, Bird C, et al. Establishment of the first WHO Erythropoietin antibody reference panel: Report of an international collaborative study. J Immunol Methods 2016; 435:32.
          </a>
         </li>
         <li class="breakAll">
          Amgen, Inc., Medical Information. Direct communication, June 16, 2005.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asari A, Gokal R. Pure red cell aplasia secondary to epoetin alpha responding to Darbepoetin alpha in a patient on peritoneal dialysis. J Am Soc Nephrol 2004; 15:2204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Summers SA, Matijevic A, Almond MK. Successful re-introduction of recombinant human erythropoietin following antibody induced pure red cell aplasia. Nephrol Dial Transplant 2004; 19:2137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macdougall IC, Roche A, Rossert J, et al. Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done? Nephrol Dial Transplant 2004; 19:2901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossert J, Macdougall I, Casadevall N. Antibody-mediated pure red cell aplasia (PRCA) treatment and re-treatment: multiple options. Nephrol Dial Transplant 2005; 20 Suppl 4:iv23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim SK, Bee PC, Keng TC, Chong YB. Resolution of epoetin-induced pure red cell aplasia 2 years later, successful re-challenge with continuous erythropoiesis receptor stimulator. Clin Nephrol 2013; 80:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirai K, Ookawara S, Miyazawa H, et al. Successful treatment of a hemodialyzed patient with pure red cell aplasia associated with epoetin beta pegol therapy with cyclosporine. CEN Case Rep 2016; 5:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viron B, Dupuy CA, Kolta A, Casadevall N. Successful re-challenge with darbepoetin in a patient with rHu-EPO-induced pure red cell aplasia refractory to immunosuppressive drugs. Nephrol Dial Transplant 2008; 23:2416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verhelst D, Rossert J, Casadevall N, et al. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 2004; 363:1768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chng WJ, Tan LK, Liu TC. Cyclosporine treatment for patients with CRF who developed pure red blood cell aplasia following EPO therapy. Am J Kidney Dis 2003; 41:692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mandreoli M, Finelli C, Lopez A, et al. Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. Am J Kidney Dis 2004; 44:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comont T, Bournet B, Casadevall N, et al. Rituximab in pure red-cell aplasia secondary to anti-erythropoietin antibodies. Kidney Int 2014; 86:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hashimoto K, Harada M, Kamijo Y. Pure red cell aplasia induced by anti-erythropoietin antibodies, well-controlled with tacrolimus. Int J Hematol 2016; 104:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennett CL, Cournoyer D, Carson KR, et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 2005; 106:3343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Covic A, Cannata-Andia J, Cancarini G, et al. Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council. Nephrol Dial Transplant 2008; 23:3731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu Y, Cai X, Ni J, Lin X. Resolution of epoetin-induced pure red cell aplasia, successful re-challenge with roxadustat. Int J Lab Hematol 2020; 42:e291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wan K, Yin Y, Luo Z, Cheng J. Remarkable response to roxadustat in a case of anti-erythropoietin antibody-mediated pure red cell aplasia. Ann Hematol 2021; 100:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu R, Peng Y. Roxadustat on anti-erythropoietin antibody-related pure red cell aplasia in the patient with end-stage renal disease. Semin Dial 2021; 34:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cai KD, Zhu BX, Lin HX, Luo Q. Successful application of roxadustat in the treatment of patients with anti-erythropoietin antibody-mediated renal anaemia: a case report and literature review. J Int Med Res 2021; 49:3000605211005984.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang H, Huang Z, He L, et al. Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor. Ren Fail 2020; 42:860.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1930 Version 36.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11167735" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Pure red cell aplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11844847" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7471674" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Anemia due to bone marrow failure: diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1201224" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Pure red cell aplasia: studies on an IgG serum inhibitor neutralizing erythropoietin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11844855" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Drug-induced autoimmune red-cell aplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8592526" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Autoantibodies against erythropoietin in a patient with pure red-cell aplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9450795" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32664894" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Antibody-mediated pure red cell aplasia related with epoetin-beta pegol (C.E.R.A.) as an erythropoietic agent: case report of a dialysis patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32269436" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Acquired Pure Red Cell Aplasia Following Recombinant Erythropoietin (Darbepoetin-alfa) Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14747386" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Anti-erythropoietin antibodies and pure red cell aplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12686654" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Pure red-cell aplasia due to anti-erythropoietin antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15009075" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Pure red cell aplasia in patients with refractory anaemia treated with two different recombinant erythropoietins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12501870" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Immunogenicity of therapeutic proteins: clinical implications and future prospects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15459301" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pure red-cell aplasia and epoetin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9181281" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Antibodies to recombinant human erythropoietin causing pure red cell aplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8676964" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12015400" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Pure red-cell aplasia and recombinant erythropoietin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15882278" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15466278" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15827058" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25239637" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14741076" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14741076" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14741076" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17556324" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Pure red-cell aplasia "epidemic"--mystery completely revealed?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18482185" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Epoetin-associated pure red cell aplasia: past, present, and future considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34980800" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Successful Treatment of Antibody-mediated Pure Red Cell Aplasia Induced by Continuous Erythropoietin Receptor Activator with Prednisolone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15138876" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Antierythropoietin antibody-induced pure red cell aplasia: posttransplant evolution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21430643" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22185963" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α(HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27478604" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Pure red cell aplasia induced by epoetin zeta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29921734" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15264184" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : A cross-sectional immunosurveillance study of anti-EPO antibody levels in CRF patients receiving epoetin alfa in 5 Ontario Renal Centers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17164586" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Prevalence of anti-erythropoietin antibodies in hemodialysis patients without clinical signs of pure red cell aplasia. Comparison between hypo- and normoresponsive patients treated with epoetins for renal anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25018948" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Chapter 1: Diagnosis and evaluation of anemia in CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15522059" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12191983" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18178785" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Pure red cell aplasia induced by erythropoiesis-stimulating agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15056991" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15827053" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27173074" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Establishment of the first WHO Erythropoietin antibody reference panel: Report of an international collaborative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27173074" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Establishment of the first WHO Erythropoietin antibody reference panel: Report of an international collaborative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15284306" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Pure red cell aplasia secondary to epoetin alpha responding to Darbepoetin alpha in a patient on peritoneal dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15252175" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Successful re-introduction of recombinant human erythropoietin following antibody induced pure red cell aplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15496566" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15827054" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Antibody-mediated pure red cell aplasia (PRCA) treatment and re-treatment: multiple options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23298519" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Resolution of epoetin-induced pure red cell aplasia 2 years later, successful re-challenge with continuous erythropoiesis receptor stimulator.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28509169" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Successful treatment of a hemodialyzed patient with pure red cell aplasia associated with epoetin beta pegol therapy with cyclosporine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18388118" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Successful re-challenge with darbepoetin in a patient with rHu-EPO-induced pure red cell aplasia refractory to immunosuppressive drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15172775" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12612995" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Cyclosporine treatment for patients with CRF who developed pure red blood cell aplasia following EPO therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15384028" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24978384" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Rituximab in pure red-cell aplasia secondary to anti-erythropoietin antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27338269" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Pure red cell aplasia induced by anti-erythropoietin antibodies, well-controlled with tacrolimus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16099877" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18802209" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32856389" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Resolution of epoetin-induced pure red cell aplasia, successful re-challenge with roxadustat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32940725" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Remarkable response to roxadustat in a case of anti-erythropoietin antibody-mediated pure red cell aplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34128578" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Roxadustat on anti-erythropoietin antibody-related pure red cell aplasia in the patient with end-stage renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33853432" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Successful application of roxadustat in the treatment of patients with anti-erythropoietin antibody-mediated renal anaemia: a case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32814474" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
